BCM
CCXI

Bayesian Capital Management’s ChemoCentryx, Inc. CCXI Stock Holding History

Bayesian Capital Management’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-19,600
Closed -$486K – 1104
2022
Q2 		$486K Buy
+19,600
New +$432K 0.09% 342

Other funds holding CCXI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SFM
Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Bayesian Capital Management's CCXI Position: Q3 2022 in Review

Bayesian Capital Management sold out of ChemoCentryx, Inc. (CCXI) in Q3 2022, closing a stake of 19,600 shares — an estimated $486K sold.

Bayesian Capital Management first reported a position in CCXI in Q2 2022 and held it in 1 quarter. The position peaked at $486K in Q2 2022. 217 funds tracked by Wall St. Rank hold CCXI as of Q3 2022.

  • Bayesian Capital Management reported no remaining ChemoCentryx, Inc. position as of Q3 2022 after selling out during the quarter.
  • Bayesian Capital Management sold 19,600 ChemoCentryx, Inc. shares in Q3 2022, an estimated $486K.
  • Bayesian Capital Management first reported a position in ChemoCentryx, Inc. in Q2 2022 and held it in 1 quarter.
  • Bayesian Capital Management's ChemoCentryx, Inc. position peaked at $486K in Q2 2022.
  • 217 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q3 2022.

Based on Bayesian Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.